CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alterity Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alterity Therapeutics Ltd
L 3 460 Bourke Street
Phone: +61 393494906p:+61 393494906 MELBOURNE, VIC  3000  Australia Ticker: ATHATH

Business Summary
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20196/30/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer Geoffrey P.Kempler 6/16/2005 11/11/1997
Chief Financial Officer KathrynAndrews 11/4/2014 11/4/2014
Chief Medical Officer and Senior Vice President Clinical Development DavidStamler 5/15/2017 5/15/2017
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Alterity Therapeutics Inc.
Alterity Therapeutics UK Limited
ATH
PBT

General Information
Number of Employees: 15 (As of 6/30/2015)
Outstanding Shares: 860,837,432 (As of 6/30/2019)
Shareholders: 3,470
Stock Exchange: ASX
Fax Number: +61 398227735


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 14, 2019